Strong Q1 Results from GSK and AstraZeneca Boost UK Pharma Sector

Key Facts

The pharmaceutical sector showed robust performance in the first quarter, as AstraZeneca and GSK exceeded UK market expectations, while U.S.-based Regeneron also posted strong results. GSK reported a core operating profit of £2.65 billion, while AstraZeneca beat estimates fueled by its oncology portfolio. In the United States, Regeneron's profit and revenue surpassed analyst estimates, driven by strong sales of Dupixent and Libtayo. However, the positive momentum faces regulatory headwinds following warnings over the impact of the U.S. 'Most Favored Nation' (MFN) policy. This pricing policy could potentially restrict drug availability in Europe and affect the global competitiveness of pharma giants. Consequently, analysts are weighing these strong financial results against emerging geopolitical and international pricing risks.

Version History